Lake Oswego, OR - January 08, 2026 - PRESSADVANTAGE - At Tersigni Vision, a growing number of patients are asking ...
The strategy summarises the case for change, identifies road safety targets and outlines an approach to monitoring the ...
Searching the IRIS Registry for the years 2016 to 2022, they found data entered for 67,855,466 patients. Applying the ICD ...
Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...
Turkey: A pilot study published in BMC Ophthalmology suggests that a gamified, app-based multimodal visual therapy may offer ...
Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing ...
Background/Aims On 17 September 2024, over 3000 pager devices containing explosives were remotely detonated across Lebanon in ...
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases ...
Dr. Michael Rothman recounts the origin of the Rothman Index and explains how overlooked nursing assessments became the key ...
The top read ophthalmology articles of 2025 focused on a variety of topics within the field, including links between ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, ...
Ocugen (OCGN) rated Buy as OCU410ST Stargardt trial advances; FDA/EMA alignment speeds path to approval. Read here for more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback